BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
Rhea-AI Summary
BioRestorative (NASDAQ:BRTX) announced that IP Australia allowed Patent Application No. 2020265664 on Feb. 24, 2026, covering non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates and methods of making them.
The allowance extends ThermoStem®'s Australian IP protection, focuses on an allogeneic, off-the-shelf BADSC platform for obesity and metabolic disorders, and signals continued global patent portfolio building for next-generation, cell-based alternatives to GLP-1 drugs.
Positive
- Australian patent allowance dated Feb 24, 2026
- Broad claim on 3D BADSC aggregates manufacturing method
- Strengthens ThermoStem® IP position for obesity/metabolic disorders
Negative
- Allowance currently limited to Australia
- Claims cover a manufacturing method, not therapeutic claims
News Market Reaction – BRTX
On the day this news was published, BRTX gained 37.01%, reflecting a significant positive market reaction. Argus tracked a peak move of +55.6% during that session. Our momentum scanner triggered 58 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $779K to the company's valuation, bringing the market cap to $3M at that time. Trading volume was exceptionally heavy at 34.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BRTX was down 9.98% while peer moves were mixed: APM up 4.13%, XTLB up 2.18%, BCTX down 3.59%, BIVI down 0.79%, and PHGE flagged in momentum scans moving up 5.49%. This points to stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Equity offering closed | Neutral | +16.1% | Closed $5.0M public offering with shares and warrants at $0.35. |
| Feb 11 | Equity offering priced | Neutral | -35.4% | Priced $5.0M offering of 14,285,715 Units at $0.35. |
| Feb 11 | Positive FDA meeting | Positive | -35.4% | Positive Type B FDA meeting on expedited BLA path for BRTX-100. |
| Feb 10 | Phase 2 enrollment complete | Positive | -38.9% | Completed enrollment of 99 patients in Phase 2 BRTX-100 cLDD trial. |
| Nov 17 | FDA meeting granted | Positive | -6.8% | FDA granted Type B meeting on potential accelerated BLA pathway. |
Positive FDA and clinical milestones for BRTX-100 have previously seen sharp negative price reactions, indicating a pattern where upbeat clinical/regulatory news coincides with selling pressure.
Over recent months, BioRestorative has advanced its BRTX-100 spine program with completion of enrollment in a 99-patient Phase 2 trial and a positive Type B FDA meeting endorsing the proposed Phase 3 design and expedited BLA pathway. Concurrently, the company raised about $5.0M via a public offering priced at $0.35 per Unit. Despite these milestones, several positive BRTX-100 updates were followed by double-digit share price declines, contrasting with a mixed reaction to financing events. Today’s ThermoStem® patent expansion adds IP strength alongside this ongoing clinical and capital-raising trajectory.
Market Pulse Summary
The stock surged +37.0% in the session following this news. A strong positive reaction aligns with the strategic importance of broader ThermoStem® IP protection in a market where GLP-1 drugs dominate obesity treatment. Historical data show that even clearly positive BRTX-100 milestones sometimes led to sharp declines (e.g., moves of -35.41% and -38.87%), highlighting event-driven volatility. Investors reviewing such a surge would have needed to weigh this new patent strength against a backdrop of prior capital raises and a stock trading far below its 2.2799 52-week high.
Key Terms
glp-1 drugs medical
cell-based therapeutic candidates medical
regenerative medicine medical
stem cell-based therapies medical
intellectual property regulatory
allogeneic medical
off-the-shelf medical
brown adipose-derived stem cell medical
AI-generated analysis. Not financial advice.
- GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks.
- BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages.
MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.”
The newly allowed patent application provides the broadest protection obtained for BioRestorative’s allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem® technology, designed to treat obesity and metabolic disorders. The claims covered are: a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.
With this allowance, BioRestorative is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, which continue to be one of the fastest-growing therapeutic categories in the world.
“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem®.”
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
What did BioRestorative (BRTX) announce on Feb. 24, 2026 regarding ThermoStem®?
How does the IP Australia allowance affect BioRestorative (BRTX) patent protection?
What exactly do the allowed claims for BRTX's Australian patent cover?
Will the Australian patent allowance change ThermoStem®'s development plans for obesity treatments?
Does the allowed Australian patent mean global exclusivity for BioRestorative (BRTX)?
